CUTIA-B (02487) announced that on August 28, 2025, the company entered into placement agreements with various placing agents. The placing agents have agreed to act as placing agents to procure placees on a best efforts basis to subscribe for an aggregate of 28.904 million shares at HK$8.40 per share, representing approximately 9.05% of the company's issued shares (excluding treasury shares) as of the announcement date. The placement price of HK$8.40 per share represents a discount of approximately 12.04% to the closing price of HK$9.55 per share on August 28, 2025. After deducting related fees and expenses, the net proceeds from the placement are expected to be approximately HK$240 million. The company intends to use the net proceeds from the placement as follows: approximately 45% of the net proceeds will be used for the company's preclinical research and development and clinical trials in the pipelines of localized fat accumulation management, hair diseases and care, skin diseases and care, and topical anesthesia, as well as for the layout of corresponding production facilities and equipment; approximately 45% of the net proceeds will be used for marketing activities, channel expansion and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam); approximately 10% of the net proceeds will be used for working capital and other general corporate purposes.